POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Clinical trials for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for transplant patients with rare lymphoma: drug duo aims to replace harsh chemo
Disease control Recruiting nowThis study tests a combination of two drugs (polatuzumab vedotin and rituximab) as the first treatment for a rare blood cancer called PTLD that can occur after an organ or stem cell transplant. The goal is to see if this combo is safe and works better than the current standard, w…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 08:27 UTC
-
Engineered immune cells take on Post-Transplant virus
Disease control Recruiting nowThis study tests a new treatment for Epstein-Barr virus (EBV) infection that can occur after a stem cell transplant. The treatment uses specially engineered immune cells (EBV-TCR-T cells) to find and attack the virus. About 18 adults who have had a stem cell transplant and still …
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New cell therapy targets dangerous EBV virus in transplant patients
Disease control Recruiting nowThis study tests a new treatment called EBV-AST cells for people who have an EBV virus infection after a stem cell transplant. The goal is to find the safest dose and see if it can clear the virus from the blood. About 18 adults aged 18-75 will take part. The treatment uses speci…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Smart bomb for lymphoma: targeted drug trial seeks to shrink tumors
Disease control Recruiting nowThis phase 2 trial tests whether loncastuximab tesirine can shrink tumors in 20 adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug is a targeted therapy that attaches to a protein on cancer cells and delivers a chemotherapy agent directl…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:53 UTC